25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

VVY (Vivoryon) Stock Analysis
Buy, Hold or Sell?

Let's analyze Vivoryon together

I guess you are interested in Vivoryon Therapeutics NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Vivoryon’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Vivoryon’s Price Targets

I'm going to help you getting a better view of Vivoryon Therapeutics NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Vivoryon Therapeutics NV

I send you an email if I find something interesting about Vivoryon Therapeutics NV.

1. Quick Overview

1.1. Quick analysis of Vivoryon (30 sec.)










1.2. What can you expect buying and holding a share of Vivoryon? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.30
Expected worth in 1 year
€-2.52
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
€-2.82
Return On Investment
-193.4%

For what price can you sell your share?

Current Price per Share
€1.46
Expected price per share
€0.92 - €1.67
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Vivoryon (5 min.)




Live pricePrice per Share (EOD)
€1.46
Intrinsic Value Per Share
€-9.66 - €-5.88
Total Value Per Share
€-9.36 - €-5.58

2.2. Growth of Vivoryon (5 min.)




Is Vivoryon growing?

Current yearPrevious yearGrowGrow %
How rich?$9.2m$30.8m-$21.5m-233.5%

How much money is Vivoryon making?

Current yearPrevious yearGrowGrow %
Making money-$24.1m-$33.2m$9.1m37.8%
Net Profit Margin0.0%782.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Vivoryon (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#598 / 881

Most Revenue
#852 / 881

Most Profit
#672 / 881

Most Efficient
#170 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Vivoryon?

Welcome investor! Vivoryon's management wants to use your money to grow the business. In return you get a share of Vivoryon.

First you should know what it really means to hold a share of Vivoryon. And how you can make/lose money.

Speculation

The Price per Share of Vivoryon is €1.46. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vivoryon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vivoryon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.30. Based on the TTM, the Book Value Change Per Share is €-0.71 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vivoryon.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps-0.93-63.4%-0.93-63.4%-1.28-87.4%-1.16-79.2%-0.96-65.5%-0.71-48.5%
Usd Book Value Change Per Share-0.83-56.7%-0.83-56.7%-0.01-0.7%-0.13-8.9%-0.31-21.5%0.042.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.83-56.7%-0.83-56.7%-0.01-0.7%-0.13-8.9%-0.31-21.5%0.042.4%
Usd Price Per Share2.34-2.34-9.55-8.00-11.37-12.76-
Price to Earnings Ratio-2.52--2.52--7.49--6.52--14.58--21.33-
Price-to-Total Gains Ratio-2.82--2.82--947.21--307.66--197.71-575,380.36-
Price to Book Ratio6.58-6.58-8.07-8.27-12.74-15,095.32-
Price-to-Total Gains Ratio-2.82--2.82--947.21--307.66--197.71-575,380.36-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.713456
Number of shares583
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.83-0.31
Usd Total Gains Per Share-0.83-0.31
Gains per Quarter (583 shares)-483.02-182.61
Gains per Year (583 shares)-1,932.08-730.44
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1932-19420-730-740
20-3864-38740-1461-1470
30-5796-58060-2191-2200
40-7728-77380-2922-2930
50-9660-96700-3652-3660
60-11592-116020-4383-4390
70-13525-135340-5113-5120
80-15457-154660-5843-5850
90-17389-173980-6574-6580
100-19321-193300-7304-7310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.014.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%6.08.00.042.9%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.014.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%6.08.00.042.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Vivoryon Therapeutics NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.706-0.7060%-0.009-99%-0.111-84%-0.267-62%0.030-2440%
Book Value Per Share--0.3020.3020%1.008-70%0.776-61%0.794-62%0.561-46%
Current Ratio--7.1967.1960%9.369-23%8.655-17%10.340-30%12.937-44%
Debt To Asset Ratio--0.3020.3020%0.147+105%0.201+50%0.210+44%0.251+20%
Debt To Equity Ratio--0.4320.4320%0.173+150%0.263+64%0.281+54%0.470-8%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--48468947.92048468947.9200%207636817.120-77%182266047.013-73%261280641.808-81%291601630.472-83%
Eps---0.789-0.7890%-1.087+38%-0.985+25%-0.815+3%-0.603-24%
Free Cash Flow Per Share---0.736-0.7360%-0.846+15%-0.806+10%-0.683-7%-0.386-47%
Free Cash Flow To Equity Per Share---0.736-0.7360%-0.846+15%-0.379-48%-0.434-41%0.117-728%
Gross Profit Margin--1.0001.0000%1.0000%1.103-9%1.163-14%1.230-19%
Intrinsic Value_10Y_max---5.882----------
Intrinsic Value_10Y_min---9.663----------
Intrinsic Value_1Y_max---0.431----------
Intrinsic Value_1Y_min---0.856----------
Intrinsic Value_3Y_max---1.416----------
Intrinsic Value_3Y_min---2.684----------
Intrinsic Value_5Y_max---2.546----------
Intrinsic Value_5Y_min---4.621----------
Market Cap38057528.000-36%51872947.92051872947.9200%212183817.120-76%177688713.680-71%252639441.808-79%283444135.272-82%
Net Profit Margin----0%7.829-100%2.610-100%1.331-100%0.665-100%
Operating Margin----0%-0%-0%-0.2380%-0.1190%
Operating Ratio----0%-6.8210%-2.2740%-0.9260%-0.4630%
Pb Ratio4.830-36%6.5836.5830%8.073-18%8.268-20%12.735-48%15095.321-100%
Pe Ratio-1.850+27%-2.522-2.5220%-7.487+197%-6.521+159%-14.585+478%-21.333+746%
Price Per Share1.460-36%1.9901.9900%8.140-76%6.817-71%9.692-79%10.874-82%
Price To Free Cash Flow Ratio-1.985+27%-2.705-2.7050%-9.621+256%-8.221+204%-16.916+525%-11855.046+438148%
Price To Total Gains Ratio-2.068+27%-2.819-2.8190%-947.215+33503%-307.665+10814%-197.705+6914%575380.364-100%
Quick Ratio--0.0450.0450%3.149-99%4.181-99%7.216-99%33.033-100%
Return On Assets---1.823-1.8230%-0.919-50%-1.213-33%-0.942-48%-389.909+21291%
Return On Equity---2.610-2.6100%-1.078-59%-1.584-39%-1.229-53%-887.950+33919%
Total Gains Per Share---0.706-0.7060%-0.009-99%-0.111-84%-0.267-62%0.030-2440%
Usd Book Value--9247968.0009247968.0000%30844555.200-70%23733321.600-61%24280845.120-62%17152593.772-46%
Usd Book Value Change Per Share---0.829-0.8290%-0.010-99%-0.130-84%-0.313-62%0.035-2440%
Usd Book Value Per Share--0.3550.3550%1.183-70%0.910-61%0.931-62%0.658-46%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--56883157.27956883157.2790%243682568.572-77%213907432.775-73%306638961.226-81%342223673.522-83%
Usd Eps---0.926-0.9260%-1.276+38%-1.157+25%-0.957+3%-0.708-24%
Usd Free Cash Flow---22504953.600-22504953.6000%-25883748.000+15%-24660465.600+10%-20884212.000-7%-11815165.071-47%
Usd Free Cash Flow Per Share---0.863-0.8630%-0.993+15%-0.946+10%-0.801-7%-0.453-47%
Usd Free Cash Flow To Equity Per Share---0.863-0.8630%-0.993+15%-0.445-48%-0.509-41%0.137-728%
Usd Market Cap44664314.861-36%60878091.67960878091.6790%249018927.772-76%208535474.375-71%296497648.906-79%332650037.155-82%
Usd Price Per Share1.713-36%2.3352.3350%9.553-76%8.000-71%11.375-79%12.761-82%
Usd Profit---24138604.800-24138604.8000%-33262171.200+38%-30148219.200+25%-24934540.320+3%-18448522.560-24%
Usd Revenue----0%-4248432.0000%-1416144.0000%1676839.680-100%838419.840-100%
Usd Total Gains Per Share---0.829-0.8290%-0.010-99%-0.130-84%-0.313-62%0.035-2440%
 EOD+3 -5MRQTTM+0 -0YOY+11 -213Y+9 -245Y+6 -2810Y+5 -29

3.3 Fundamental Score

Let's check the fundamental score of Vivoryon Therapeutics NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.850
Price to Book Ratio (EOD)Between0-14.830
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.045
Current Ratio (MRQ)Greater than17.196
Debt to Asset Ratio (MRQ)Less than10.302
Debt to Equity Ratio (MRQ)Less than10.432
Return on Equity (MRQ)Greater than0.15-2.610
Return on Assets (MRQ)Greater than0.05-1.823
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Vivoryon Therapeutics NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.466
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Vivoryon Therapeutics NV

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.

Fundamental data was last updated by Penke on 2025-06-17 18:08:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Vivoryon earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Vivoryon to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ €0.00 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY782.9%-782.9%
TTM-5Y133.1%-133.1%
5Y133.1%10Y66.5%+66.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--88.2%+88.2%
TTM--141.5%+141.5%
YOY782.9%-182.9%+965.8%
3Y261.0%-247.7%+508.7%
5Y133.1%-338.6%+471.7%
10Y66.5%-473.1%+539.6%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Vivoryon is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Vivoryon to theΒ Biotechnology industry mean.
  • -182.3% Return on Assets means thatΒ Vivoryon generatedΒ €-1.82 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vivoryon Therapeutics NV:

  • The MRQ is -182.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -182.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-182.3%TTM-182.3%0.0%
TTM-182.3%YOY-91.9%-90.3%
TTM-182.3%5Y-94.2%-88.1%
5Y-94.2%10Y-38,990.9%+38,896.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-182.3%-11.1%-171.2%
TTM-182.3%-11.2%-171.1%
YOY-91.9%-11.0%-80.9%
3Y-121.3%-11.6%-109.7%
5Y-94.2%-11.8%-82.4%
10Y-38,990.9%-13.6%-38,977.3%
4.3.1.3. Return on Equity

Shows how efficient Vivoryon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Vivoryon to theΒ Biotechnology industry mean.
  • -261.0% Return on Equity means Vivoryon generated €-2.61Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vivoryon Therapeutics NV:

  • The MRQ is -261.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -261.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-261.0%TTM-261.0%0.0%
TTM-261.0%YOY-107.8%-153.2%
TTM-261.0%5Y-122.9%-138.1%
5Y-122.9%10Y-88,795.0%+88,672.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-261.0%-12.8%-248.2%
TTM-261.0%-14.2%-246.8%
YOY-107.8%-14.1%-93.7%
3Y-158.4%-16.6%-141.8%
5Y-122.9%-17.3%-105.6%
10Y-88,795.0%-19.4%-88,775.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Vivoryon Therapeutics NV.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Vivoryon is operatingΒ .

  • Measures how much profit Vivoryon makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Vivoryon to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-23.8%+23.8%
5Y-23.8%10Y-11.9%-11.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--227.4%+227.4%
TTM--253.9%+253.9%
YOY--201.7%+201.7%
3Y--214.9%+214.9%
5Y-23.8%-339.9%+316.1%
10Y-11.9%-444.7%+432.8%
4.3.2.2. Operating Ratio

Measures how efficient Vivoryon is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-6.821+6.821
TTM-5Y-0.926+0.926
5Y-0.92610Y-0.463-0.463
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.060-2.060
TTM-2.737-2.737
YOY-6.8212.997-9.818
3Y-2.2743.496-5.770
5Y-0.9264.660-5.586
10Y-0.4636.353-6.816
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Vivoryon Therapeutics NV.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Vivoryon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 7.20Β means the company has €7.20 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 7.196. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.196. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.196TTM7.1960.000
TTM7.196YOY9.369-2.173
TTM7.1965Y10.340-3.144
5Y10.34010Y12.937-2.597
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1963.670+3.526
TTM7.1963.745+3.451
YOY9.3694.121+5.248
3Y8.6554.623+4.032
5Y10.3405.733+4.607
10Y12.9376.143+6.794
4.4.3.2. Quick Ratio

Measures if Vivoryon is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Vivoryon to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.05Β means the company can pay off €0.05 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.045. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.045. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.045TTM0.0450.000
TTM0.045YOY3.149-3.104
TTM0.0455Y7.216-7.171
5Y7.21610Y33.033-25.817
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0452.906-2.861
TTM0.0453.128-3.083
YOY3.1493.786-0.637
3Y4.1814.308-0.127
5Y7.2165.703+1.513
10Y33.0336.411+26.622
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Vivoryon Therapeutics NV.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of VivoryonΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Vivoryon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.30Β means that Vivoryon assets areΒ financed with 30.2% credit (debt) and the remaining percentage (100% - 30.2%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.302. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.302. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.302TTM0.3020.000
TTM0.302YOY0.147+0.154
TTM0.3025Y0.210+0.092
5Y0.21010Y0.251-0.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3020.328-0.026
TTM0.3020.356-0.054
YOY0.1470.335-0.188
3Y0.2010.339-0.138
5Y0.2100.350-0.140
10Y0.2510.383-0.132
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Vivoryon is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Vivoryon to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 43.2% means that company has €0.43 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.432. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.432. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.432TTM0.4320.000
TTM0.432YOY0.173+0.259
TTM0.4325Y0.281+0.151
5Y0.28110Y0.470-0.189
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4320.384+0.048
TTM0.4320.436-0.004
YOY0.1730.413-0.240
3Y0.2630.447-0.184
5Y0.2810.464-0.183
10Y0.4700.512-0.042
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Vivoryon generates.

  • Above 15 is considered overpriced butΒ always compareΒ Vivoryon to theΒ Biotechnology industry mean.
  • A PE ratio of -2.52 means the investor is paying €-2.52Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is -1.850. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.522. Based on the earnings, the company is expensive. -2
  • The TTM is -2.522. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.850MRQ-2.522+0.672
MRQ-2.522TTM-2.5220.000
TTM-2.522YOY-7.487+4.965
TTM-2.5225Y-14.585+12.063
5Y-14.58510Y-21.333+6.748
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.850-2.125+0.275
MRQ-2.522-2.027-0.495
TTM-2.522-2.541+0.019
YOY-7.487-3.670-3.817
3Y-6.521-3.716-2.805
5Y-14.585-6.057-8.528
10Y-21.333-6.591-14.742
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is -1.985. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.705. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.705. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.985MRQ-2.705+0.720
MRQ-2.705TTM-2.7050.000
TTM-2.705YOY-9.621+6.916
TTM-2.7055Y-16.916+14.211
5Y-16.91610Y-11,855.046+11,838.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.985-3.030+1.045
MRQ-2.705-2.710+0.005
TTM-2.705-3.805+1.100
YOY-9.621-4.404-5.217
3Y-8.221-5.103-3.118
5Y-16.916-8.536-8.380
10Y-11,855.046-9.228-11,845.818
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Vivoryon is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 6.58 means the investor is paying €6.58Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is 4.830. Based on the equity, the company is fair priced.
  • The MRQ is 6.583. Based on the equity, the company is overpriced. -1
  • The TTM is 6.583. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.830MRQ6.583-1.753
MRQ6.583TTM6.5830.000
TTM6.583YOY8.073-1.490
TTM6.5835Y12.735-6.152
5Y12.73510Y15,095.321-15,082.586
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.8301.900+2.930
MRQ6.5831.861+4.722
TTM6.5832.162+4.421
YOY8.0732.465+5.608
3Y8.2682.527+5.741
5Y12.7353.682+9.053
10Y15,095.3214.351+15,090.970
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets11,284
Total Liabilities3,404
Total Stockholder Equity7,880
 As reported
Total Liabilities 3,404
Total Stockholder Equity+ 7,880
Total Assets = 11,284

Assets

Total Assets11,284
Total Current Assets10,067
Long-term Assets1,217
Total Current Assets
Cash And Cash Equivalents 9,365
Short-term Investments 63
Other Current Assets 639
Total Current Assets  (as reported)10,067
Total Current Assets  (calculated)10,067
+/-0
Long-term Assets
Property Plant Equipment 124
Long-term Assets Other 228
Long-term Assets  (as reported)1,217
Long-term Assets  (calculated)352
+/- 865

Liabilities & Shareholders' Equity

Total Current Liabilities1,399
Long-term Liabilities2,005
Total Stockholder Equity7,880
Total Current Liabilities
Accounts payable 1,015
Other Current Liabilities 324
Total Current Liabilities  (as reported)1,399
Total Current Liabilities  (calculated)1,339
+/- 60
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt102
Long-term Liabilities  (as reported)2,005
Long-term Liabilities  (calculated)102
+/- 1,903
Total Stockholder Equity
Total Stockholder Equity (as reported)7,880
Total Stockholder Equity (calculated)0
+/- 7,880
Other
Capital Stock261
Net Invested Capital 7,880
Net Working Capital 8,668
Property Plant and Equipment Gross 124



6.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
> Total Assets 
15,966
19,093
10,005
6,374
21
22
22
11
4
45,861
29,751
24,520
31,378
30,829
11,284
11,28430,82931,37824,52029,75145,8614112222216,37410,00519,09315,966
   > Total Current Assets 
7,590
11,032
9,009
5,949
21
22
22
11
4
45,377
28,793
20,229
30,694
29,812
10,067
10,06729,81230,69420,22928,79345,3774112222215,9499,00911,0327,590
       Cash And Cash Equivalents 
6,061
9,295
7,726
4,879
21
21
22
10
4
41,524
26,306
14,661
26,555
18,562
9,365
9,36518,56226,55514,66126,30641,5244102221214,8797,7269,2956,061
       Short-term Investments 
27
1,028
2
186
101
0
0
0
0
0
21
7
7
10,021
63
6310,02177210000010118621,02827
       Net Receivables 
0
0
0
0
0
125
166
46
91
602
129
3,360
3,965
0
0
003,9653,360129602914616612500000
       Inventory 
42
18
18
0
0
-125
-166
-46
-91
0
0
0
0
0
0
000000-91-46-166-12500181842
   > Long-term Assets 
8,376
8,061
996
425
0
0
0
0
0
484
958
4,291
684
1,017
1,217
1,2171,0176844,291958484000004259968,0618,376
       Property Plant Equipment 
1,549
1,264
926
321
0
0
0
0
0
465
390
285
176
76
124
12476176285390465000003219261,2641,549
       Goodwill 
1,996
1,996
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001,9961,996
       Intangible Assets 
4,828
4,798
67
101
0
0
0
0
0
16
565
533
494
941
0
09414945335651600000101674,7984,828
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
3,473
14
0
0
00143,47300000000000
> Total Liabilities 
3,727
4,148
4,640
10,598
6
6
6
2
3
3,196
3,530
7,963
4,872
4,547
3,404
3,4044,5474,8727,9633,5303,1963266610,5984,6404,1483,727
   > Total Current Liabilities 
3,090
3,136
3,570
9,333
5
5
5
1
1
930
1,325
5,051
3,265
3,182
1,399
1,3993,1823,2655,0511,325930115559,3333,5703,1363,090
       Short-term Debt 
0
0
0
5,346
0
0
0
0
83
91
90
92
94
0
0
00949290918300005,346000
       Accounts payable 
938
1,215
731
1,327
1
2
2
0
1
1
1
4
3
2,894
1,015
1,0152,8943411102211,3277311,215938
       Other Current Liabilities 
2,152
1,921
2,839
24
4
3
3
0
0
839
1,235
4,959
3,171
1
324
32413,1714,9591,23583900334242,8391,9212,152
   > Long-term Liabilities 
637
1,012
1,070
1,265
929
822
850
1,171
1,854
2,266
2,205
2,912
1,607
1,365
2,005
2,0051,3651,6072,9122,2052,2661,8541,1718508229291,2651,0701,012637
       Other Liabilities 
0
0
0
0
0
0
850
1,171
1,854
1,951
1,981
2,780
1,569
0
0
001,5692,7801,9811,9511,8541,171850000000
> Total Stockholder Equity
12,239
14,945
5,365
-4,224
16
16
16
9
1
42,665
26,221
16,557
26,506
26,282
7,880
7,88026,28226,50616,55726,22142,66519161616-4,2245,36514,94512,239
   Common Stock
15,718
22,694
25,529
25,529
7
7
8
8
8
19,975
19,975
20,050
24,105
0
0
0024,10520,05019,97519,9758887725,52925,52922,69415,718
   Retained Earnings -169,367-148,799-120,457-92,300-79,646-63,136-55-48-40-26-12-81,745-71,816-53,096-36,789
   Capital Surplus 000000000000000
   Treasury Stock000000000000000
   Other Stockholders Equity 
33,310
45,347
51,652
51,992
22
34
48
48
48
86,388
86,547
89,379
123,038
0
0
00123,03889,37986,54786,388484848342251,99251,65245,34733,310



6.3. Balance Sheets

Currency in EUR. All numbers in thousands.




6.4. Cash Flows

Currency in EUR. All numbers in thousands.




6.5. Income Statements

Currency in EUR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-20,964
Operating Income-20,964-20,964
 
Operating Expense (+$)
Research Development14,058
Selling General Administrative6,903
Selling And Marketing Expenses0
Operating Expense20,96420,961
 
Net Interest Income (+$)
Interest Income482
Interest Expense-86
Other Finance Cost-0
Net Interest Income396
 
Pretax Income (+$)
Operating Income-20,964
Net Interest Income396
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-20,568-20,964
EBIT - interestExpense = -86
-20,568
-20,482
Interest Expense86
Earnings Before Interest and Taxes (EBIT)0-20,482
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-20,568
Tax Provision-0
Net Income From Continuing Ops-20,568-20,568
Net Income-20,568
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-396
 

Technical Analysis of Vivoryon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vivoryon. The general trend of Vivoryon is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vivoryon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Vivoryon Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vivoryon Therapeutics NV.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.55 < 1.654 < 1.67.

The bearish price targets are: 1.324 > 0.999 > 0.92.

Know someone who trades $VVY? Share this with them.πŸ‘‡

Vivoryon Therapeutics NV Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vivoryon Therapeutics NV. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vivoryon Therapeutics NV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Moving Average Convergence/Divergence (MACD) ChartVivoryon Therapeutics NV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vivoryon Therapeutics NV. The current adx is .

Vivoryon Therapeutics NV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Relative Strength Index (RSI) ChartVivoryon Therapeutics NV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Stochastic Oscillator ChartVivoryon Therapeutics NV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Commodity Channel Index (CCI) ChartVivoryon Therapeutics NV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Chande Momentum Oscillator (CMO) ChartVivoryon Therapeutics NV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Williams %R ChartVivoryon Therapeutics NV Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Average True Range (ATR) ChartVivoryon Therapeutics NV Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily On-Balance Volume (OBV) ChartVivoryon Therapeutics NV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vivoryon Therapeutics NV.

Vivoryon Therapeutics NV Daily Money Flow Index (MFI) ChartVivoryon Therapeutics NV Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vivoryon Therapeutics NV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Vivoryon Therapeutics NV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Vivoryon Therapeutics NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.466
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Vivoryon with someone you think should read this too:
  • Are you bullish or bearish on Vivoryon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Vivoryon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Vivoryon Therapeutics NV

I send you an email if I find something interesting about Vivoryon Therapeutics NV.


Comments

How you think about this?

Leave a comment

Stay informed about Vivoryon Therapeutics NV.

Receive notifications about Vivoryon Therapeutics NV in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.